This finding challenges the notion that IFN-β properties in MS/EAE are uniformly protective or that MG near CNS lesions during EAE upregulates endogenous IFN-β production as part of the healing process (Khorooshi et al., 2015; Kocur et al., 2015). The gene discussed is IFNB1; the disease is myeloid sarcoma.